Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

CD30 CAR for CD30+ NSGCT

Phase 2

Recruiting

Conditions: Germ Cell Tumor
Nonseminomatous Germ Cell Tumor

Interventions: Biological: ATLCAR.CD30 Cells
Drug: Cyclophosphamid
Drug: Fludarabine

First Posted Date: 2022-12-02

Last Posted Date: 2024-10-26

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 18

Registration Number: NCT05634785

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2

Recruiting

Conditions: Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Grade 3b Follicular Lymphoma
Transformed Follic Lymph to Diff Large B-Cell Lymphoma

Interventions: Biological: Axicabtagene Ciloleucel
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Cyclophosphamide
Biological: Mosunetuzumab
Other: Patient Observation
Drug: Fludarabine
Drug: Polatuzumab Vedotin
Biological: Lisocabtagene Maraleucel
Procedure: Positron Emission Tomography
Biological: Tisagenlecleucel

First Posted Date: 2022-12-01

Last Posted Date: 2024-12-20

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 396

Registration Number: NCT05633615

Locations: 🇺🇸
Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas, United States
🇺🇸
Highlands Oncology Group - Rogers, Rogers, Arkansas, United States
🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States

and more 73 locations

TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL

Phase 1

Recruiting

Conditions: Non-hodgkin Lymphoma,B Cell

Interventions: Biological: Autologous CD19-STAR-T cell
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2022-11-30

Last Posted Date: 2023-07-06

Lead Sponsor: Chinese PLA General Hospital

Target Recruit Count: 38

Registration Number: NCT05631912

Locations: 🇨🇳
Biotherapeutic Department, Chinese PLA General Hospital, Beijing, Beijing, China
🇨🇳
School of medicine, Tsinghua University & Changping Laboratory, Beijing, Beijing, China

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Phase 1

Recruiting

Conditions: Unresectable Melanoma
Non-Cutaneous Melanoma
Metastatic Melanoma
Ocular Melanoma
Iris Melanoma
Acral Melanoma
Uveal Melanoma
Mucosal Melanoma
Cutaneous Melanoma
Conjunctival Melanoma

Interventions: Biological: TBio-4101
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Interleukin-2

First Posted Date: 2022-11-29

Last Posted Date: 2024-11-27

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 25

Registration Number: NCT05628883

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes) for the Treatment of Primary Central Nervous System Lymphoma

Phase 1

Recruiting

Conditions: Central Nervous System Lymphoma

Interventions: Procedure: Aspiration
Procedure: Biospecimen Collection
Procedure: Catheterization
Biological: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Fludarabine
Procedure: Leukapheresis
Procedure: Lumbar Puncture
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2022-11-23

Last Posted Date: 2024-07-11

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 20

Registration Number: NCT05625594

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

Phase 3

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: Nemtabrutinib
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Bendamustine
Biological: Rituximab
Biological: Truxima
Biological: Ruxience
Biological: Riabni

First Posted Date: 2022-11-22

Last Posted Date: 2024-12-24

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 300

Registration Number: NCT05624554

Locations: 🇺🇸
Highlands Oncology Group ( Site 5205), Springdale, Arkansas, United States
🇺🇸
Clermont Oncology Center ( Site 5224), Clermont, Florida, United States
🇺🇸
Hattiesburg Clinic Hematology/Oncology ( Site 5216), Hattiesburg, Mississippi, United States

and more 94 locations

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

Phase 1

Recruiting

Conditions: Non Hodgkin's Lymphoma Refractory/Relapsed

Interventions: Biological: CD19t-haNK suspension
Drug: N803
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Rituximab

First Posted Date: 2022-11-16

Last Posted Date: 2024-08-20

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 20

Registration Number: NCT05618925

Locations: 🇺🇸
Hoag Memorial Hospital, Newport Beach, California, United States

CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome

Phase 2

Suspended

Conditions: Graft Vs Host Disease
Graft-versus-host-disease
Myelodysplastic Syndromes

Interventions: Drug: Busulfan
Drug: Melphalan
Drug: Fludarabine
Device: CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)

First Posted Date: 2022-11-15

Last Posted Date: 2024-11-25

Lead Sponsor: Guenther Koehne

Target Recruit Count: 50

Registration Number: NCT05617625

Locations: 🇺🇸
Miami Cancer Institute, Miami, Florida, United States

BGT007 Cell Treatment of Nasopharyngeal Carcinoma

Early Phase 1

Recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Biological: BGT007 Cell Injection
Drug: Fludarabine
Drug: cyclophosphamide

First Posted Date: 2022-11-15

Last Posted Date: 2022-12-15

Lead Sponsor: The Affiliated Hospital of Xuzhou Medical University

Target Recruit Count: 23

Registration Number: NCT05616468

Locations: 🇨🇳
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

Phase 3

Recruiting

Conditions: High-risk Large B-cell Lymphoma (LBCL)

Interventions: Biological: Axicabtagene Ciloleucel
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Rituximab
Drug: Fludarabine
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2022-11-04

Last Posted Date: 2024-12-24

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 300

Registration Number: NCT05605899

Locations: 🇫🇷
CHU Bordeaux-Hopital Haut-Leveque, Bordeaux, France
🇫🇷
Centre Leon Berard, Cedex Lyon 08, France
🇫🇷
CHU Dijon, Dijon, France

and more 87 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy